Search - tctmd.com

Displaying 1 - 20 of 34

Sort: Relevancy | Date

News Conference News TCT 2025

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

Todd Neale

November 03, 2025

Presentation TCT 2024

TCT 505: Impact of Low-Dose Prasugrel on 1-Month and 12-Month Serial Vessel Responses After Coronary Stent Implantation

Presenter: Takayuki Ishihara

October 30, 2024

Presentation TCT 2024

TCT 426: One-Year Clinical Outcome of Prasugrel Monotherapy After PCI for Chronic Coronary Syndrome in Japanese Population

Presenter: KOTARO MIYASHITA

October 29, 2024

Presentation TCT 2024

TCT 231: Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

Presenter: KOTARO MIYASHITA

October 27, 2024

Presentation TCT 2024

TCT 6: Aspirin-Free Prasugrel Monotherapy After PCI in Patients With Non-ST Elevation Acute Coronary Syndrome

Presenter: KOTARO MIYASHITA

October 27, 2024

Presentation TCT 2023

TCT 165: Aspirin-Free Prasugrel Monotherapy: Thirty Days Clinical Outcome after Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non-ST Segment Elevation Acute Coronary Syndrome

Presenter: Gaku Nakazawa

October 26, 2023

News Conference News TCT 2023

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

Yael L. Maxwell

October 25, 2023

Presentation TCT 2022

TCT 46: Prehospital crushed versus integral prasugrel loading dose in patients presenting with anterior ST-segment elevation myocardial infarction – A COMPARE CRUSH subanalysis

Presenter: Rosanne Vogel

September 17, 2022

Presentation TCT 2022

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

Presenter: Yoshinobu Onuma

September 17, 2022

Presentation TCT 2022

TCT 28: Pharmacodynamic response, early reperfusion and clinical outcomes to pre-hospital prasugrel administration in diabetic patients presenting with STEMI – A COMPARE CRUSH subanalysis

Presenter: Rosanne Vogel

September 17, 2022

Presentation TCT 2022

TCT 27: Ticagrelor versus Prasugrel in an All-Comer Patient Cohort undergoing Percutaneous Coronary Intervention

Presenter: Anoop Koshy

September 17, 2022

Presentation TCT 2022

TCT 24: Ticagrelor versus Prasugrel in Acute Myocardial Infarction for East Asians

Presenter: Ji sung KIM

September 17, 2022

Presentation TCT 2022

TCT 23: Influence of the circadian clock on the pharmacodynamic effect of prasugrel in patients presenting with ST-segment elevation myocardial infarction – A COMPARE CRUSH subanalysis

Presenter: Rosanne Vogel

September 17, 2022

Presentation TCT 2022

TCT 19: Thrombin Generation and Endothelial Progenitor Cell Function in Patients with Acute Myocardial Infarction Treated with Prasugrel versus Ticagrelor

Presenter: Mark Kheifets

September 17, 2022

News Conference News TCT 2021

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

Caitlin E. Cox

November 06, 2021

News Conference News TCT 2021

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Shelley Wood

November 05, 2021

Presentation TCT 2021

Prasugrel De-escalation Therapy After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Subgroup Analysis of the HOST-REDUCE-POLYTECH-ACS Randomized Clinical Trial

Presenter: Doyeon Hwang

November 04, 2021

News Conference News TCT 2021

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Yael L. Maxwell

October 22, 2021

News Conference News TCT 2021

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

Yael L. Maxwell

October 15, 2021

Presentation TCT 2020

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention: The COMPARE CRUSH Trial

Presenter: George Vlachojannis

October 14, 2020

Advertisement

Ultrathin-Strut DES Performs Well vs Xience in Diabetic Patients: TUXEDO-2

TCT 505: Impact of Low-Dose Prasugrel on 1-Month and 12-Month Serial Vessel Responses After Coronary Stent Implantation

TCT 426: One-Year Clinical Outcome of Prasugrel Monotherapy After PCI for Chronic Coronary Syndrome in Japanese Population

TCT 231: Safety of Aspirin-Free Prasugrel Monotherapy After PCI: Pooled Analysis of Three Months Outcomes in 508 Patients From ASET-I and ASET-Japan Trials

TCT 6: Aspirin-Free Prasugrel Monotherapy After PCI in Patients With Non-ST Elevation Acute Coronary Syndrome

TCT 165: Aspirin-Free Prasugrel Monotherapy: Thirty Days Clinical Outcome after Percutaneous Coronary Intervention in Chronic Coronary Syndrome and Non-ST Segment Elevation Acute Coronary Syndrome

In ACS, Ticagrelor Only After < 1 Month DAPT Beats Continuing Aspirin: T-PASS

TCT 46: Prehospital crushed versus integral prasugrel loading dose in patients presenting with anterior ST-segment elevation myocardial infarction – A COMPARE CRUSH subanalysis

TCT 14: A 30-day Pooled Analysis of Acetyl Salicylic Elimination Trials (ASET) Post PCI in Brazil and Japan : SYNERGY Stent with Prasugrel Monotherapy (10 or 3.75 mg )

TCT 28: Pharmacodynamic response, early reperfusion and clinical outcomes to pre-hospital prasugrel administration in diabetic patients presenting with STEMI – A COMPARE CRUSH subanalysis

TCT 27: Ticagrelor versus Prasugrel in an All-Comer Patient Cohort undergoing Percutaneous Coronary Intervention

TCT 24: Ticagrelor versus Prasugrel in Acute Myocardial Infarction for East Asians

TCT 23: Influence of the circadian clock on the pharmacodynamic effect of prasugrel in patients presenting with ST-segment elevation myocardial infarction – A COMPARE CRUSH subanalysis

TCT 19: Thrombin Generation and Endothelial Progenitor Cell Function in Patients with Acute Myocardial Infarction Treated with Prasugrel versus Ticagrelor

Magnetic Endoscopy Capsule Reveals GI Damage Surprises From Antiplatelets

More DAPT Duration Data, More Calls to Tailor to Individual Patients

Prasugrel De-escalation Therapy After Complex Percutaneous Coronary Intervention in Acute Coronary Syndrome: A Subgroup Analysis of the HOST-REDUCE-POLYTECH-ACS Randomized Clinical Trial

De-escalating Prasugrel Reduces Net Events in Complex PCI for ACS

Crushed Prasugrel Loading Dose Still No Benefit at 1 Year in COMPARE CRUSH

Effect of pre-hospital crushed prasugrel tablets in patients with STEMI planned for primary percutaneous coronary intervention: The COMPARE CRUSH Trial

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content